ReviewWiener klinische Wochenschrift2026
Evolving landscape of glioblastoma research : A 75-year bibliometric study on survival, treatment and gender in authorship.
Review in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlioblastoma is the most aggressive type of brain tumor. Here, we examine the evolution of glioblastoma treatment and survival across different study types over nearly a century. Furthermore, we map the landscape of glioblastoma research to track the potential influence of publication bias on perceived progress and assess sex disparities in authorship across time, study type and geographic region.
methodsWe analyzed a comprehensive dataset of glioblastoma research published from 1947-2022. A manual review of 19,668 articles yielded 2232 articles passing the inclusion criteria.
resultsOverall, we observed an increased median overall survival (OS, slope = 0.16 months per year, Pearson's r = 0.23, p = 1.65e-44) for all study types. Nevertheless, reported survival outcomes varied by treatment modality. Only tumor treating fields (fitted median OS from 14.5 to 21.4 months, slope = 0.53 months per year) showed a stronger increase in positive outcomes than radiotherapy with concomitant and adjuvant temozolomide (fitted median overall survival from 12.0 to 20.0 months, slope = 0.31 months per year). Despite making up only 5.6% of all studies, randomized controlled trials had the highest cumulative impact factor and citation count and US-based researchers dominated across all study types (33.9%). Women continued to be underrepresented, particularly as last authors (25.2% female first, 18.5% female last).
conclusionThe 75 years of reported survival of patients with glioblastoma document a slow increase in overall survival. While research by women as first authors shows an upward trend, gender inequality persists, particularly in the last authorship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.